NNVC · Nanoviricides, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that the Company’s cash and cash equivalents balance of approximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2022-08-08 | Diwan Anil |
Director, President |
Gift↓
Filing footnotes — Common Stock, par value $0.001 per share (Direct)
The reported transaction involves a gift made by the reporting person for estate planning purposes to an irrevocable trust whose beneficiaries are his minor children and of which he is neither the trustee nor a beneficiary. Does not include 6,074 shares of Series A Convertible Preferred Stock (the "Series A Stock") owned by the reporting person which is convertible into three and one-half shares of common stock upon limited conditions. Does not include 200,000 shares of Series A Stock or 470,959 shares of common stock owned by TheraCour Pharma, Inc., over which the reporting person holds voting and dispositive power. |
Common Stock, par value $0.001 per share
|
94,471 |